#NewAseBioMember | "AseBio es el punto de encuentro del ecosistema biotecnológico en España, una plataforma clave de representación, colaboración y conexión entre empresas, instituciones y agentes del sector"
Meet StablePharma Spain, our new member. We spoke with Lorena Carmona Rodríguez, Lab Manager/Senior Scientist.
AseBio. What does your company's work bring to the table and what is its strength?
Lorena Carmona Rodríguez. Stablepharma provides an innovative solution to one of the major global challenges in healthcare: dependence on the cold chain. We develop thermostabilisation technologies that enable vaccines and biological products to be stored and distributed without refrigeration, improving access, reducing costs, and minimising waste. Our main strength lies in our technology platform, our scientific expertise, and our collaborative approach with industrial partners.
AseBio. What is AseBio for you?
Lorena Carmona Rodríguez. AseBio is a key meeting point for the Spanish biotechnology ecosystem, acting as a platform for representation, collaboration, and connection between companies, institutions, and stakeholders across the sector.
AseBio. When did you first hear about AseBio?
Lorena Carmona Rodríguez. We first heard about AseBio at an industry event held at Qube Park, which highlighted its role as a benchmark and driving force for biotechnology in Spain.
AseBio. What do you expect from being part of an association like AseBio?
Lorena Carmona Rodríguez. We expect to strengthen our visibility within the sector, actively contribute to the development of the regulatory and strategic landscape, and build new collaborations that drive innovation and the advancement of biotechnological solutions.
AseBio. What is the biggest challenge facing the biotech sector or your company?
Lorena Carmona Rodríguez. The biggest challenge is turning scientific innovation into real-world solutions with global impact, while also ensuring scalability, sustainability, and fair access to key technologies—such as, in our case, the thermostabilisation of pharmaceutical products that require the cold chain to maintain their effectiveness.